Literature DB >> 26380568

Treatment of Generalized Convulsive Status Epilepticus in Pediatric Patients.

Elizabeth L Alford1, James W Wheless2, Stephanie J Phelps3.   

Abstract

Generalized convulsive status epilepticus (GCSE) is one of the most common neurologic emergencies and can be associated with significant morbidity and mortality if not treated promptly and aggressively. Management of GCSE is staged and generally involves the use of life support measures, identification and management of underlying causes, and rapid initiation of anticonvulsants. The purpose of this article is to review and evaluate published reports regarding the treatment of impending, established, refractory, and super-refractory GCSE in pediatric patients.

Entities:  

Keywords:  anticonvulsants; pediatrics; status epilepticus

Year:  2015        PMID: 26380568      PMCID: PMC4557718          DOI: 10.5863/1551-6776-20.4.260

Source DB:  PubMed          Journal:  J Pediatr Pharmacol Ther        ISSN: 1551-6776


  209 in total

1.  How long do new-onset seizures in children last?

Authors:  S Shinnar; A T Berg; S L Moshe; R Shinnar
Journal:  Ann Neurol       Date:  2001-05       Impact factor: 10.422

2.  Intranasal versus intravenous lorazepam for control of acute seizures in children: a randomized open-label study.

Authors:  Ravindra Arya; Sheffali Gulati; Madhulika Kabra; Jitendra K Sahu; Veena Kalra
Journal:  Epilepsia       Date:  2011-01-28       Impact factor: 5.864

3.  Very-high-dose phenobarbital for childhood refractory status epilepticus.

Authors:  Wai Kin Lee; Kam Tim Liu; Betty Wan Yin Young
Journal:  Pediatr Neurol       Date:  2006-01       Impact factor: 3.372

4.  Clinical effects and toxicokinetic evaluation following massive topiramate ingestion.

Authors:  Michael J Lynch; Anthony F Pizon; Mohamed G Siam; Matthew D Krasowski
Journal:  J Med Toxicol       Date:  2010-06

5.  Eight-year study of childhood status epilepticus: midazolam infusion in management and outcome.

Authors:  Roshan Koul; Alexander Chacko; Hashim Javed; Kassim Al Riyami
Journal:  J Child Neurol       Date:  2002-12       Impact factor: 1.987

6.  Relapse and survival after barbiturate anesthetic treatment of refractory status epilepticus.

Authors:  K B Krishnamurthy; F W Drislane
Journal:  Epilepsia       Date:  1996-09       Impact factor: 5.864

7.  Five cases of new onset refractory status epilepticus (NORSE) syndrome: outcomes with early immunotherapy.

Authors:  Claire R E Gall; Odai Jumma; Rajiv Mohanraj
Journal:  Seizure       Date:  2013-01-18       Impact factor: 3.184

Review 8.  The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions.

Authors:  Michael A Rogawski; Wolfgang Löscher
Journal:  Nat Med       Date:  2004-07       Impact factor: 53.440

9.  Status epilepticus in children, adults, and the elderly.

Authors:  R J DeLorenzo; A R Towne; J M Pellock; D Ko
Journal:  Epilepsia       Date:  1992       Impact factor: 5.864

10.  A comparison of buccal midazolam and intravenous diazepam for the acute treatment of seizures in children.

Authors:  Seyed-Hassan Tonekaboni; Farhad Mahvelati Shamsabadi; Seyed-Saeed Anvari; Ali Mazrooei; Mohammad Ghofrani
Journal:  Iran J Pediatr       Date:  2012-09       Impact factor: 0.364

View more
  4 in total

Review 1.  Medication-Induced Tardive Dyskinesia: A Review and Update.

Authors:  Elyse M Cornett; Matthew Novitch; Alan David Kaye; Vijay Kata; Adam M Kaye
Journal:  Ochsner J       Date:  2017

Review 2.  Management of Status Epilepticus in Children.

Authors:  Douglas M Smith; Emily L McGinnis; Diana J Walleigh; Nicholas S Abend
Journal:  J Clin Med       Date:  2016-04-13       Impact factor: 4.241

Review 3.  An Insight into the Current Understanding of Status Epilepticus: From Concept to Management.

Authors:  Khouloud Abdulrhman Al-Sofyani
Journal:  Neurol Res Int       Date:  2021-07-13

Review 4.  Advances in Pediatric Pharmacology, Therapeutics, and Toxicology.

Authors:  Laura A Wang; Michael Cohen-Wolkowiez; Daniel Gonzalez
Journal:  Adv Pediatr       Date:  2016-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.